NEW YORK (GenomeWeb News) — Prodesse said today it will stop selling three of its multiplex ASR products in the US Aug. 1 as it transitions them into in vitro diagnostics in light of a recent US Food and Drug Administration draft guidance.
 
The company said it plans to remove the underlying supermixes for its Hexaplex, Hexaplex Plus, and ProPneumo-1 products as part of an “orderly transition” from ASRs to IVD assays.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.